Two Sigma Advisers
TARS icon

Two Sigma Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History

Two Sigma Advisers’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,100
Closed -$745K – 1902
2025
Q4 		$745K Buy
+9,100
New +$679K ﹤0.01% 1629
2025
Q1 		– Sell
-53,500
Closed -$2.96M – 2576
2024
Q4 		$2.96M Sell
53,500
-202,900
-79% -$9.22M 0.01% 938
2024
Q3 		$8.43M Sell
256,400
-51,200
-17% -$1.44M 0.02% 532
2024
Q2 		$8.36M Buy
307,600
+233,700
+316% +$7.86M 0.02% 593
2024
Q1 		$2.69M Buy
73,900
+7,600
+11% +$223K 0.01% 1069
2023
Q4 		$1.34M Buy
66,300
+5,200
+9% +$86.8K ﹤0.01% 1489
2023
Q3 		$1.09M Buy
61,100
+30,800
+102% +$545K ﹤0.01% 1483
2023
Q2 		$548K Buy
+30,300
New +$482K ﹤0.01% 1778
2023
Q1 		– Sell
-26,700
Closed -$391K – 2746
2022
Q4 		$391K Sell
26,700
-5,400
-17% -$89.4K ﹤0.01% 1973
2022
Q3 		$550K Buy
32,100
+21,500
+203% +$341K ﹤0.01% 1805
2022
Q2 		$155K Buy
+10,600
New +$159K ﹤0.01% 2326

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Advisers's TARS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 9,100 shares — an estimated $745K sold.

Two Sigma Advisers first reported a position in TARS in Q2 2022 and held it in 11 quarters. The position peaked at $8.43M in Q3 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 9,100 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $745K.
  • Two Sigma Advisers first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Two Sigma Advisers's Tarsus Pharmaceuticals position peaked at $8.43M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.